Park Medi World Share Price Delivers 90% Return in 2026 So Far: More Upside Ahead? Analysts Decode

Park Medi World shares have turned strong performers in 2026, rising about 90% year-to-date. Choice Broking expects more upside, estimating nearly 20% further gains with a revised target of ₹350 per share, supported by capacity additions and recent financial improvements across revenue, margins and profits.

The stock has rewarded early investors since listing. Park Medi World share price debuted at ₹158.80 each in December 2025 and is now trading almost 80% higher than the issue price. The healthcare stock has also delivered sharp short-term gains over the past week and month.

Park Medi World share price and quarterly financial performance

Recent quarterly numbers have added support for Park Medi World share price, according to the brokerage review. For Q4 FY26, reported on 12 May, consolidated net profit attributable to owners of the company increased 58% year-on-year to ₹70.9 crore, compared with ₹44.8 crore in the same period last year.

The company's overall net profit after tax also advanced during the quarter. Consolidated PAT rose 47% year-on-year to ₹76.8 crore, versus ₹52.4 crore a year earlier. Revenue from operations climbed 30% to ₹460.4 crore, up from ₹353.9 crore, reflecting higher patient volumes and improved efficiency across hospitals.

Operating performance strengthened as well, supporting analyst optimism around Park Medi World share price. EBITDA for Q4 FY26 rose 44% year-on-year to ₹127.4 crore. EBITDA margin improved to 27.7%, compared with 25.0% in the same quarter of the previous financial year, pointing towards better cost management and operating leverage.

Park Medi World share price, capacity expansion and growth plans

Alongside financial gains, the company has expanded its hospital network, which is another driver tracked by Park Medi World share price watchers. Exchange filings stated that Park Medi World lifted its capacity by 20% during FY26 by adding 610 beds, aided by acquisitions in Bhatinda and Agra.

These additions lifted total capacity to 3,610 beds as of 31 March 2026. Choice Broking highlighted this expansion, saying the management expects Park Hospitals' growth to come from aggressive capacity build-up, better capital allocation, optimised average length of stay, richer case mix, improved payor mix and updated CGHS rate benefits.

During an interaction with the brokerage, the management outlined medium-term targets that are relevant for Park Medi World share price assessments. By the second year, revenues are expected to reach ₹1,400 million, implying 40% year-on-year growth, with EBITDA estimated at ₹35 million, giving a 25% margin, and PAT of ₹21 million, implying a 15% margin.

These forecasts assume occupancy levels rising to 70-75% across facilities. Explaining the backdrop, the report noted: "The management's confidence is supported by strong promoter commitment, a healthy financial position, proven execution capability and access to capital. The company turned debt-free in February 2026 and continues to generate healthy operating cash flows, providing financial flexibility for expansion."

Park Medi World share price movement and analyst view

Despite the strong year-to-date trend, Park Medi World share price traded slightly weaker on Wednesday. On the NSE, the stock was quoted at ₹285.19 per share, marginally below the previous close, even as the broader trajectory since listing has stayed positive for investors who entered at launch.

The newly listed healthcare stock has delivered multibagger-type returns so far in 2026. On a year-to-date basis, the Park Medi World share price is up nearly 90%. The stock has gained around 11% over the past week and about 20.50% during the last month, showing strong interest from market participants.

Choice Broking, in its latest note, reaffirmed a 'buy' call on the healthcare company while raising the target for Park Medi World share price to ₹350 per share. The firm cited ongoing capacity expansion, improving operational metrics and strengthened balance sheet as reasons for expecting around 20% further upside from current levels.